Literature DB >> 19695714

Expression of Th1 and Th17 cytokines and transcription factors in multiple sclerosis patients: does baseline T-bet mRNA predict the response to interferon-beta treatment?

Jelena Drulovic1, Emina Savic, Tatjana Pekmezovic, Sarlota Mesaros, Nebojsa Stojsavljevic, Irena Dujmovic-Basuroski, Jelena Kostic, Vladimir Vasic, Marija Mostarica Stojkovic, Dusan Popadic.   

Abstract

We studied the effect of one-year interferon (IFN)-beta treatment on the in vivo mRNA expression of IFN-gamma, interleukin (IL)-17, T-bet and RoR-gammat, on peripheral blood mononuclear cells (PBMC) from 36 multiple sclerosis (MS) patients. In the total MS group, IFN-beta induced decrease in mRNA levels of IFN-gamma and T-bet (p<0.0001), while the levels of IL-17 and RoR-gammat remained similar. In both responders and non-responders, IFN-beta induced significant decrease of IFN-gamma (p<0.0001 and p=0.011, respectively), while decrease in T-bet was detected only in responders (p<0.0001). Higher pre-treatment T-bet allowed prediction of the clinical response in the first year (beta=0.601, p=0.036). Our preliminary findings suggest that T-bet expression might be a potential prognostic marker of treatment response to IFN-beta in MS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19695714     DOI: 10.1016/j.jneuroim.2009.07.010

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  15 in total

1.  miR-29ab1 deficiency identifies a negative feedback loop controlling Th1 bias that is dysregulated in multiple sclerosis.

Authors:  Kristen M Smith; Mireia Guerau-de-Arellano; Stefan Costinean; Jessica L Williams; Arianna Bottoni; Gina Mavrikis Cox; Abhay R Satoskar; Carlo M Croce; Michael K Racke; Amy E Lovett-Racke; Caroline C Whitacre
Journal:  J Immunol       Date:  2012-07-06       Impact factor: 5.422

Review 2.  T-bet in disease.

Authors:  Vanja Lazarevic; Laurie H Glimcher
Journal:  Nat Immunol       Date:  2011-06-20       Impact factor: 25.606

Review 3.  IL-17 and limits of success.

Authors:  Zahra Omidian; Rizwan Ahmed; Adebola Giwa; Thomas Donner; Abdel Rahim A Hamad
Journal:  Cell Immunol       Date:  2018-09-17       Impact factor: 4.868

Review 4.  Single nucleotide polymorphisms in multiple sclerosis: disease susceptibility and treatment response biomarkers.

Authors:  Vera Pravica; Dusan Popadic; Emina Savic; Milos Markovic; Jelena Drulovic; Marija Mostarica-Stojkovic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

Review 5.  Th1 versus Th17: are T cell cytokines relevant in multiple sclerosis?

Authors:  Amy E Lovett-Racke; Yuhong Yang; Michael K Racke
Journal:  Biochim Biophys Acta       Date:  2010-06-18

Review 6.  More than just a T-box: the role of T-bet as a possible biomarker and therapeutic target in autoimmune diseases.

Authors:  Niannian Ji; Rebecca A Sosa; Thomas G Forsthuber
Journal:  Immunotherapy       Date:  2011-03       Impact factor: 4.196

7.  Smad7 in T cells drives T helper 1 responses in multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  Ingo Kleiter; Jian Song; Dominika Lukas; Maruf Hasan; Bernhard Neumann; Andrew L Croxford; Xiomara Pedré; Nadine Hövelmeyer; Nir Yogev; Alexander Mildner; Marco Prinz; Elena Wiese; Kurt Reifenberg; Stefan Bittner; Heinz Wiendl; Lawrence Steinman; Christoph Becker; Ulrich Bogdahn; Markus F Neurath; Andreas Steinbrecher; Ari Waisman
Journal:  Brain       Date:  2010-03-30       Impact factor: 13.501

8.  Dysregulation of Th1, Th2, Th17, and T regulatory cell-related transcription factor signaling in children with autism.

Authors:  Sheikh Fayaz Ahmad; Khairy M A Zoheir; Mushtaq Ahmad Ansari; Ahmed Nadeem; Saleh A Bakheet; Laila Yousef Al-Ayadhi; Mohammad Zeed Alzahrani; Othman A Al-Shabanah; Mohammed M Al-Harbi; Sabry M Attia
Journal:  Mol Neurobiol       Date:  2016-06-25       Impact factor: 5.590

Review 9.  DNA Methylation: a New Player in Multiple Sclerosis.

Authors:  Xiang Li; Bing Xiao; Xing-Shu Chen
Journal:  Mol Neurobiol       Date:  2016-06-17       Impact factor: 5.590

10.  Excessive biologic response to IFNβ is associated with poor treatment response in patients with multiple sclerosis.

Authors:  Richard A Rudick; M R Sandhya Rani; Yaomin Xu; Jar-Chi Lee; Jie Na; Jennifer Shrock; Anupama Josyula; Elizabeth Fisher; Richard M Ransohoff
Journal:  PLoS One       Date:  2011-05-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.